Ładuje się......
Candidate Surrogate End Points for ESRD after AKI
AKI, a frequently transient condition, is not accepted by the US Food and Drug Association as an end point for drug registration trials. We assessed whether an intermediate-term change in eGFR after AKI has a sufficiently strong relationship with subsequent ESRD to serve as an alternative end point...
Zapisane w:
| Wydane w: | J Am Soc Nephrol |
|---|---|
| Główni autorzy: | , , , , , , , , , , |
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
American Society of Nephrology
2016
|
| Hasła przedmiotowe: | |
| Dostęp online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5004655/ https://ncbi.nlm.nih.gov/pubmed/26857682 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2015070829 |
| Etykiety: |
Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!
|